Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant acinetobacter baumannii

International Journal of Infectious Diseases

Volumn 38, Issue , 2015, Pages 32-35

  Gulen, Tugba Arslan ^a   Guner, Rahmet ^b   Celikbilek, Nevreste ^c   Keske, Siran ^d   Tasyaran, Mehmet ^b  

^a Nigde State Hospital   (Turkey)

^b YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d GIRESUN UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Cost; Multi drug resistance

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; METRONIDAZOLE; QUINOLONE;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HOSPITALIZATION COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; MALE; MORTALITY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; CROSS INFECTION; DRUG EFFECTS; ECONOMICS; HOSPITAL COST; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84938796510     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.06.014     Document Type: Article

References (26)

1. Erbay H., Yalçin A.N., Serin S., Turgut H., Tomatir E., Çetin B., et al. Nosocomial infections in intensive care unit in a Turkish university hospital: a 2 year survey. Intensive Care Med 2003, 29:1482-1488.
2. Koo S.H., Kwon K.C., Cho H.H., Sung J.Y. Genetic Basis of Multidrug-resistant Acinetobacter baumannii Clinical Isolates from Three University Hospitals in Chungcheong Province, Korea. Korean J Lab Med 2010, 30:498-506.
3. Somily A.M., Absar M.M., Arshad M.Z., Al Aska A.I., Shakoor Z.A., Fatani A.J., et al. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline. Saudi Med J. 2012 Jul, 33(7):750-755.
4. Gordon N.C., Wareham D.W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Inter J Antimicrobiol Agents 2010, 35:219-226.
5. Van Looveren M., Goossens H. Antimicrobial resistance of Acinetobacter spp in Europe. Clin Microbiol Infect 2004, 10:684-704. ARPAC Steering Group.
6. Shih M.J., Lee N.Y., Lee H.C., Chang C.M., Wu C.J., Chen P.L., et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case control study. J Microbiol Immunol Infect 2008, 41:118-123.
7. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing, Twentieth Informational Supplement, M100-S20, CLSI, Wayne, PA (2009).
8. Rosenthal V.D., Maki D.G., Jamulitrat S., Medeiros E.A., Todi S.K., et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control. 2010 Mar, 38(2):95-104.
9. Mera R.M., Miller L.A., Amrine-Madsen H., Sahm D.F. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist. 2010 Sep, 16(3):209-215.
10. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13:19045.
11. Orsi G.B., Franchi C., Giordano A., Rocco M., Ferraro F., Mancini C., et al. Multidrug resistant Acinetobacter baumannii in an intensive care unit. J Chemother 2008, 20:219-224.
12. Jung J.Y., Park M.S., Kim S.H., Park B.H., Son J.Y., Kim E.Y., et al. Risk factors for multidrug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 2010, 10:228.
13. Dent L.L., Marshall D.R., Pratap S., Hulette R.B. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010, 10:196.
14. Baran G., Erbay A., Bodur H., Ongörü P., Akinci E., Balaban N., et al. Risk factors for imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008, 12:16-21.
15. García-Garmendia J.L., Ortiz-Leyba C., Garnacho-Montero J., Jiménez-Jiménez F.J., Pérez-Paredes C., Barrero-Almodóvar A.E., et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001, 33:939-946.
16. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control and Hosp Epidemiol 2007, 28(6):713-719.
17. Robenshtok E., Paul M., Leibovici L., Fraser A., Pitlik S., Ostfeld I., et al. The significance of Acinetobacter baumannii bacteremia compared with Klebsiella pneumoniae bacteremia: risk factors and outcomes. J Hosp Infect 2006, 64:282-287.
18. Towner KJ. Acinetobacter. In: Collier L, Balows A, Susman M, eds. Topley&Wilson's Microbiology and Microbial Infections. 9 th ed. London:1998; 1229-39.
19. Kim Y.J., Kim S.I., Kim Y.R., Hong K.W., Wie S.H., Park Y.J., et al. Carbapenem resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect 2011, 18:1-9.
20. Falagas M.E., Kopterides P. Risk factors for the isolation of multidrug resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15.
21. Lee S.O., Kim N.J., Choi S.H., Hyong Kim T., Chung J.W., Woo J.H., et al. Risk factors for acquisition of imipenem resistant Acinetobacter baumannii: a case control study. Antimicrob Agents and Chemother 2004, 48:224-228.
22. Maragakis L.L., Perl T.M. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
23. Hernández-Torres A., García-Vázquez E., Gómez J., Canteras M., Ruiz J., Yagüe G. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality. Med Clin (Barc). 2012 May 26, 138(15):650-655.
24. Falagas M.E., Kopterides P., Siempos I.I. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006, 43:389-390.
25. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
26. Tansarli G.S., Karageorgopoulos D.E., Kapaskelis A., Falagas M.E. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013 Mar, 11(3):321-331.